Jump to content

Granulomatous–lymphocytic interstitial lung disease: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Sections
Change to popular format for inline citations (undo this if you don't like it)
Line 1: Line 1:
{{AFC submission|t||ts=20160615071131|u=Dr John Hurst|ns=118|demo=}} <!--- Important, do not remove this line before article has been created. --->
{{AFC submission|t||ts=20160615071131|u=Dr John Hurst|ns=118|demo=}} <!--- Important, do not remove this line before article has been created. --->
'''Granulomatous–lymphocytic interstitial lung disease''' (GLILD) is a lung complication of [[common variable immunodeficiency]] disorders (CVID). It is seen in approximately 15% of patients [1]. It has been defined histologically as the presence of (non-caseating) granuloma and lymphoproliferation in the lung [1]. However, as GLILD is often associated with other auto-immune features such as splenomegaly, adenopathy and cytopenias, a definition based on abnormalities on lung imaging (CT scan) together with evidence of granulomatous inflammation elsewhere has also been employed [2]. Although infections and complications of infection such as bronchiectasis are more common complications of CVID in the lung, the presence of immune manifestations including GLILD is important because this has been associated with greater risk of death [1, 3]. In general, as a rare complication of a rare disease, the condition remains incompletely understood and there is real need for further research in the area.
'''Granulomatous–lymphocytic interstitial lung disease''' (GLILD) is a lung complication of [[common variable immunodeficiency]] disorders (CVID). It is seen in approximately 15% of patients with CVID.<ref name=":0">Bates CA, Ellison MC, Lynch DA et al. Granulomatous-lymphocytic lung disease shortens survival in common variable immunodeficiency. J Allergy Clin Immunol 2004;114:415-421 PMID 15316526</ref> It has been defined histologically as the presence of (non-caseating) granuloma and lymphoproliferation in the lung.<ref name=":0" /> However, as GLILD is often associated with other auto-immune features such as splenomegaly, adenopathy and cytopenias, a definition based on abnormalities on lung imaging (CT scan) together with evidence of granulomatous inflammation elsewhere has also been employed.<ref name=":1">Boursiquot JN, Gérard L, Malphettes M et al. Granulomatous disease in CVID: retrospective analysis of clinical characteristics and treatment efficacy in a cohort of 59 patients. J Clin Immunol 2013;33:84-95 PMID 22986767</ref> Although infections and complications of infection such as bronchiectasis are more common complications of CVID in the lung, the presence of immune manifestations including GLILD is important because this has been associated with greater risk of death.<ref name=":0" /><ref>Resnick ES, Moshier El, Godbold JH, Cunningham-Rundles C. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood 2012;119:1650-1657 PMID 22180439 [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3286343/ PMC 3286343]</ref> In general, as a rare complication of a rare disease, the condition remains incompletely understood and there is real need for further research in the area.


== Symptoms ==
== Symptoms ==
Line 6: Line 6:


== Risk factors ==
== Risk factors ==
Why only some people with CVID are affected by GLILD remains unknown. However, there have been reports that elevated IgM, altered T-cell function and/or proportionality of CD4:CD8 cells may be associated with increased risk of GLILD [4] and GLILD has also been associated with specific genetic mutations in CVID, including CTLA-4 deficiency [5, 6].
Why only some people with CVID are affected by GLILD remains unknown. However, there have been reports that elevated IgM, altered T-cell function and/or proportionality of CD4:CD8 cells may be associated with increased risk of GLILD,<ref name=":2">Verma N, Grimbacher B, Hurst JR. Lung disease in primary antibody deficiency. Lancet Respir Med 2015;3:651-660</ref> and GLILD has also been associated with specific genetic mutations in CVID, including CTLA-4 deficiency.<ref>Schubert D, Bode C, Kenefeck R et al. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med 2014;20:1410-1416 PMID 25329329 [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4668597/ PMC4668597]</ref><ref>Kuehn HS, Ouyang W, Lo B et al. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science 2014;345:1623-1627 PMID 25213377 [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4371526/ PMC4371526]</ref>


== Diagnosis ==
== Diagnosis ==
The diagnosis is usually suspected following a CT scan. Typical features on CT include solid and sub-solid nodules, ground glass change and reticulation [7]. There may be features of multi-system involvement such as adenopathy and splenomegaly. The commonest abnormality on lung function testing is a decrease in gas transfer [2]. Both obstructive and restrictive patterns on spirometry have been reported [2]. The differential diagnosis includes infection, other interstitial lung diseases and malignant disease including lymphoma. Exclusion of infection is therefore an important step in management, but confirmation of the diagnosis requires lung biopsy. In patients presenting with lung disease prior to a diagnosis of CVID, the differential diagnosis includes sarcoidosis. Sarcoid is also characterised by granulomatous involvement of the lung and therefore patients being investigated for sarcoid should have serum immunoglobulins measured to exclude CVID.
The diagnosis is usually suspected following a CT scan. Typical features on CT include solid and sub-solid nodules, ground glass change and reticulation.<ref>Park JE, Beal I, Dilworth JP, Tormey V, Haddock J. The HRCT appearances of granulomatous pulmonary disease in common variable immune deficiency. European Journal of Radiology 2005;54:359-364 PMID 15899336</ref> There may be features of multi-system involvement such as adenopathy and splenomegaly. The commonest abnormality on lung function testing is a decrease in gas transfer.<ref name=":1" /> Both obstructive and restrictive patterns on spirometry have been reported.<ref name=":1" /> The differential diagnosis includes infection, other interstitial lung diseases and malignant disease including lymphoma. Exclusion of infection is therefore an important step in management, but confirmation of the diagnosis requires lung biopsy. In patients presenting with lung disease prior to a diagnosis of CVID, the differential diagnosis includes sarcoidosis. Sarcoid is also characterised by granulomatous involvement of the lung and therefore patients being investigated for sarcoid should have serum immunoglobulins measured to exclude CVID.


== Treatment ==
== Treatment ==
There are no current guidelines available on the investigation and management of GLILD and evidence is restricted to retrospective case-series. Because of the association with poorer outcomes, and because some patients develop advanced lung disease, most specialists now recommend treatment in early disease but this is always an individual decision between patient and health-care team [4]. Many centres screen for the development of GLILD (and other lung complications) using regular lung function tests and CT scans [4].
There are no current guidelines available on the investigation and management of GLILD and evidence is restricted to retrospective case-series. Because of the association with poorer outcomes, and because some patients develop advanced lung disease, most specialists now recommend treatment in early disease but this is always an individual decision between patient and health-care team.<ref name=":2" /> Many centres screen for the development of GLILD (and other lung complications) using regular lung function tests and CT scans.<ref name=":2" />


Studies of GLILD have been conducted in patients on background immunoglobulin replacement. In a cohort of 59 CVID patients with granulomatous disease, 30 (51%) of whom had lung involvement, complete remission of disease was obtained in 5 of 25 attempts using corticosteroids (three patients), methotrexate (1 patient) and cyclophosphamide (1 patient) [2]. Partial responses were also seen with rituximab and hydroxychloroquine. In contrast, a second report suggested poor response to corticosteroids alone, but a good response to 18-months treatment with rituximab and azathioprine in seven patients [8]. Bone-marrow transplant has been attempted [9]. Immunosuppression has been associated with development of opportunistic infection [2] and other predictable side-effects, and the balance of risks and benefits of therapy must be carefully weighed in each case. This may be best achieved by joint working between immunology, respiratory, radiology and pathology specialists, working as part of a multi-professional team with the patient [4].
Studies of GLILD have been conducted in patients on background immunoglobulin replacement. In a cohort of 59 CVID patients with granulomatous disease, 30 (51%) of whom had lung involvement, complete remission of disease was obtained in 5 of 25 attempts using corticosteroids (three patients), methotrexate (1 patient) and cyclophosphamide (1 patient).<ref name=":1" /> Partial responses were also seen with rituximab and hydroxychloroquine. In contrast, a second report suggested poor response to corticosteroids alone, but a good response to 18-months treatment with rituximab and azathioprine in seven patients.<ref>Chase NM, Verbsky JW, Hintermeyer MK et al. Use of combination chemotherapy for treatment of granulomatous and lymphocytic interstitial lung disease (GLILD) in patients with common variable immunodeficiency (CVID). J Clin Immunol 2013;33:30-39 PMID 22930256 [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3557581/ PMC3557581]</ref> Bone-marrow transplant has been attempted.<ref>Wehr C, Gennery AR, Lindemans C et al. Multicenter experience in hematopoietic stem cell transplantation for serious complications of common variable immunodeficiency. J Allergy Clin Immunol 2015;135:988-97 PMID 25595268.</ref> Immunosuppression has been associated with development of opportunistic infection<ref name=":1" /> and other predictable side-effects, and the balance of risks and benefits of therapy must be carefully weighed in each case. This may be best achieved by joint working between immunology, respiratory, radiology and pathology specialists, working as part of a multi-professional team with the patient.<ref name=":2" />


There is very little information written by, and for patients with GLILD. However, interest in the condition is increasing and multi-centre studies such as STILPAD are in progress [10].
There is very little information written by, and for patients with GLILD. However, interest in the condition is increasing and multi-centre studies such as STILPAD are in progress.<ref>Centrum für Chronische Immundefizienz - CCI [https://www.uniklinik-freiburg.de/cci/studien/stilpad.html STILPAD Observational Study]. Page accessed June 20, 2016.</ref>


==References==
==References==
⚫
<references />{{AFC submission|||ts=20160615071547|u=Dr John Hurst|ns=118}}
{{reflist}}

*1. Bates CA, Ellison MC, Lynch DA et al. Granulomatous-lymphocytic lung disease shortens survival in common variable immunodeficiency. J Allergy Clin Immunol 2004;114:415-421 PMID 15316526 {{mcn}}
*2. Boursiquot JN, Gérard L, Malphettes M et al. Granulomatous disease in CVID: retrospective analysis of clinical characteristics and treatment efficacy in a cohort of 59 patients. J Clin Immunol 2013;33:84-95 PMID 22986767 {{mcn}}
*3. Resnick ES, Moshier El, Godbold JH, Cunningham-Rundles C. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood 2012;119:1650-1657 PMID 22180439 [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3286343/ PMC 3286343] {{mcn}}
*4. Verma N, Grimbacher B, Hurst JR. Lung disease in primary antibody deficiency. Lancet Respir Med 2015;3:651-660 PMID 2618888
*5. Kuehn HS, Ouyang W, Lo B et al. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science 2014;345:1623-1627 PMID 25213377 [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4371526/ PMC4371526] {{mcn}}
*6. Schubert D, Bode C, Kenefeck R et al. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med 2014;20:1410-1416 PMID 25329329 [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4668597/ PMC4668597]{{mcn}}
*7. Park JE, Beal I, Dilworth JP, Tormey V, Haddock J. The HRCT appearances of granulomatous pulmonary disease in common variable immune deficiency. European Journal of Radiology 2005;54:359-364 PMID 15899336 {{mcn}}
*8. Chase NM, Verbsky JW, Hintermeyer MK et al. Use of combination chemotherapy for treatment of granulomatous and lymphocytic interstitial lung disease (GLILD) in patients with common variable immunodeficiency (CVID). J Clin Immunol 2013;33:30-39 PMID 22930256 [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3557581/ PMC3557581] {{mcn}}
*9. Wehr C, Gennery AR, Lindemans C et al. Multicenter experience in hematopoietic stem cell transplantation for serious complications of common variable immunodeficiency. J Allergy Clin Immunol 2015;135:988-97 PMID 25595268 {{mcn}}
*10. Centrum für Chronische Immundefizienz - CCI [https://www.uniklinik-freiburg.de/cci/studien/stilpad.html STILPAD Observational Study] Page accessed June 20, 2016 {{third party}}

⚫
{{AFC submission|||ts=20160615071547|u=Dr John Hurst|ns=118}}

Revision as of 06:38, 21 June 2016

Granulomatous–lymphocytic interstitial lung disease (GLILD) is a lung complication of common variable immunodeficiency disorders (CVID). It is seen in approximately 15% of patients with CVID.[1] It has been defined histologically as the presence of (non-caseating) granuloma and lymphoproliferation in the lung.[1] However, as GLILD is often associated with other auto-immune features such as splenomegaly, adenopathy and cytopenias, a definition based on abnormalities on lung imaging (CT scan) together with evidence of granulomatous inflammation elsewhere has also been employed.[2] Although infections and complications of infection such as bronchiectasis are more common complications of CVID in the lung, the presence of immune manifestations including GLILD is important because this has been associated with greater risk of death.[1][3] In general, as a rare complication of a rare disease, the condition remains incompletely understood and there is real need for further research in the area.

Symptoms

People affected by GLILD may have symptoms such as cough and breathlessness, but may also be asymptomatic with the condition first detected through abnormalities on lung function tests or CT scan of the lungs.

Risk factors

Why only some people with CVID are affected by GLILD remains unknown. However, there have been reports that elevated IgM, altered T-cell function and/or proportionality of CD4:CD8 cells may be associated with increased risk of GLILD,[4] and GLILD has also been associated with specific genetic mutations in CVID, including CTLA-4 deficiency.[5][6]

Diagnosis

The diagnosis is usually suspected following a CT scan. Typical features on CT include solid and sub-solid nodules, ground glass change and reticulation.[7] There may be features of multi-system involvement such as adenopathy and splenomegaly. The commonest abnormality on lung function testing is a decrease in gas transfer.[2] Both obstructive and restrictive patterns on spirometry have been reported.[2] The differential diagnosis includes infection, other interstitial lung diseases and malignant disease including lymphoma. Exclusion of infection is therefore an important step in management, but confirmation of the diagnosis requires lung biopsy. In patients presenting with lung disease prior to a diagnosis of CVID, the differential diagnosis includes sarcoidosis. Sarcoid is also characterised by granulomatous involvement of the lung and therefore patients being investigated for sarcoid should have serum immunoglobulins measured to exclude CVID.

Treatment

There are no current guidelines available on the investigation and management of GLILD and evidence is restricted to retrospective case-series. Because of the association with poorer outcomes, and because some patients develop advanced lung disease, most specialists now recommend treatment in early disease but this is always an individual decision between patient and health-care team.[4] Many centres screen for the development of GLILD (and other lung complications) using regular lung function tests and CT scans.[4]

Studies of GLILD have been conducted in patients on background immunoglobulin replacement. In a cohort of 59 CVID patients with granulomatous disease, 30 (51%) of whom had lung involvement, complete remission of disease was obtained in 5 of 25 attempts using corticosteroids (three patients), methotrexate (1 patient) and cyclophosphamide (1 patient).[2] Partial responses were also seen with rituximab and hydroxychloroquine. In contrast, a second report suggested poor response to corticosteroids alone, but a good response to 18-months treatment with rituximab and azathioprine in seven patients.[8] Bone-marrow transplant has been attempted.[9] Immunosuppression has been associated with development of opportunistic infection[2] and other predictable side-effects, and the balance of risks and benefits of therapy must be carefully weighed in each case. This may be best achieved by joint working between immunology, respiratory, radiology and pathology specialists, working as part of a multi-professional team with the patient.[4]

There is very little information written by, and for patients with GLILD. However, interest in the condition is increasing and multi-centre studies such as STILPAD are in progress.[10]

References

  1. ^ a b c Bates CA, Ellison MC, Lynch DA et al. Granulomatous-lymphocytic lung disease shortens survival in common variable immunodeficiency. J Allergy Clin Immunol 2004;114:415-421 PMID 15316526
  2. ^ a b c d e Boursiquot JN, Gérard L, Malphettes M et al. Granulomatous disease in CVID: retrospective analysis of clinical characteristics and treatment efficacy in a cohort of 59 patients. J Clin Immunol 2013;33:84-95 PMID 22986767
  3. ^ Resnick ES, Moshier El, Godbold JH, Cunningham-Rundles C. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood 2012;119:1650-1657 PMID 22180439 PMC 3286343
  4. ^ a b c d Verma N, Grimbacher B, Hurst JR. Lung disease in primary antibody deficiency. Lancet Respir Med 2015;3:651-660
  5. ^ Schubert D, Bode C, Kenefeck R et al. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med 2014;20:1410-1416 PMID 25329329 PMC4668597
  6. ^ Kuehn HS, Ouyang W, Lo B et al. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science 2014;345:1623-1627 PMID 25213377 PMC4371526
  7. ^ Park JE, Beal I, Dilworth JP, Tormey V, Haddock J. The HRCT appearances of granulomatous pulmonary disease in common variable immune deficiency. European Journal of Radiology 2005;54:359-364 PMID 15899336
  8. ^ Chase NM, Verbsky JW, Hintermeyer MK et al. Use of combination chemotherapy for treatment of granulomatous and lymphocytic interstitial lung disease (GLILD) in patients with common variable immunodeficiency (CVID). J Clin Immunol 2013;33:30-39 PMID 22930256 PMC3557581
  9. ^ Wehr C, Gennery AR, Lindemans C et al. Multicenter experience in hematopoietic stem cell transplantation for serious complications of common variable immunodeficiency. J Allergy Clin Immunol 2015;135:988-97 PMID 25595268.
  10. ^ Centrum für Chronische Immundefizienz - CCI STILPAD Observational Study. Page accessed June 20, 2016.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Granulomatous–lymphocytic_interstitial_lung_disease&oldid=726285210"